An E13a3 BCR‐ABL1 Fusion Transcript in Variant T(9;22;17)(q34;q11;q21)‐positive Adult Acute Lymphoblastic Leukemia
X. Zhang,Jianji Pan
DOI: https://doi.org/10.1111/ijlh.12481
2016-01-01
International Journal of Laboratory Hematology
Abstract:Sir, The Philadelphia (Ph) chromosome is formed as a result of the t(9;22)(q34;q11) and is one of the most frequent cytogenetic abnormalities in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). It is observed in at least 90–95% of CML as well as 11–30% of adult ALL [1]. The chimeric BCR-ABL1 fusion transcript is usually formed from reciprocal translocation of chromosome 9 and 22 at break point q34 and q11, respectively. Most BCR-ABL1 fusion transcripts are e13a2 (b2a2) or e14a2 (b3a2); some variant patients have been reported expressing the less commonly, e1a2 or e19a2. In addition, very rare atypical transcript types, such as e1a3, e14a3, or e6a2, have been described [2–10]. The prognostic significance of the occurrence of variant translocations and the rare atypical transcript types of BCR-ABL1 are still obscure. Herein, we describe a 39year-old woman with no known past medical history was admitted to our hospital with bleeding diathesis and weakness. Laboratory investigations showed that her white blood cell count (WBC) was 324.8 9 10/L with 75% blasts, a hemoglobin level of 9.1 g/dL, and a platelet count of 30 9 10/L. Coagulation tests revealed the following: prothrombin time 15.2 s, partial thromboplastin time 43.1 s, fibrinogen 1.53 g/L, and d-dimer 9.71 lg/ mL. Bone marrow (BM) examination was performed, and morphologic analysis of the BM aspirate showed hypercellularity and 74.5% immature lymphocytes. The immunophenotype by flow cytometric analysis was positive for HLA-DR, CD10, CD19, CD20, CD34, CD123, cCD79a, and TdT. Reverse transcriptase–polymerase chain reaction (RT-PCR) assay to amplify the fusion transcripts including e13a3 BCR-ABL1 fusion transcript (Figure 1) was positive, and other BCR-ABL1 fusion transcripts including e1a2, e13a2, e14a2, and e19a2 were negative (date not shown). cDNA sequencing of the diagnostic PCR products confirmed this variant fusion transcript (Figure 2). Hence, a diagnosis of common B-ALL was confirmed. Two weeks later, the result of cytogenetic analysis revealed that t(9;22;17)(q34;q11;q21) was positive in 16 of 20 metaphases (Figure 3). Induction therapy with VDCLP regimen (cyclophosphamide, vincristine, idarubicin, pegaspargase, and dexamethasone) and oral imatinib 400 mg per day were started. She achieved a complete molecular remission after 1 month of imatinib treatment. The e13a3 BCR-ABL1 fusion transcript was negative by RT-PCR assay, and the clonal t(9;22;17)(q34; q11;q21) was not detected by cytogenetic examination. Up to now, the patient has been administered two cycles of consolidation chemotherapy and continuous oral imatinib and she is still healthy. Previous studies have confirmed that about 5–10% of patients were with CML with variant Ph chromosome translocations [11, 12]; however, these have been less commonly reported in ALL. Most patients of CML have a p210-encoding BCR-ABL1 gene resulting from either an e13a2 or e14a2 type, while the typical finding in ALL is a p190 protein derived from an ela2 fusion gene. However, a number of rare patients have been reported with bcr break points outside the three defined cluster regions or with unusual break points in abl resulting in BCRABL1 transcripts with e13a3 types [11]. Variant Ph translocations have been more rarely reported in acute leukemias (ALs). Cho SY et al. [12] reported that there are 23 variant Ph translocations in ALL, while the types of BCR-ABL1 fusion transcripts that have been detected in these patients showed e1a2, e13a2, and e14a2 types. Herein, we report a variant Ph patient of t (9;22;17)(q34;q11;q21) in an adult ALL. On the basis of bone marrow morphology, cytogenetic analysis, reverse transcriptase–polymerase chain reaction (RT-PCR), and flow cytometry analysis, current patient was diagnosed with common B-ALL associated with both t(9;22;17)(q34; q11;q21) translocation and the type of BCR-ABL1 fusion transcript was e13a3 type. Interestingly, Robinson HM et al. [13] also reported a t(9;22;17)(q34;q11;q21) variant in an ALL patient but the type of BCR-ABL1 fusion transcript was e1a2 type and provided no clinical data. The mechanisms of the generation of the variant translocations are not known. Fluorescence in situ hybridization (FISH) is the technique used at present to